Sanofi’s Post

We are thrilled to announce the release of the latest edition of Sanofi's Code of Conduct! This comprehensive guide is more than just a document—it's a testament to our unwavering commitment to integrity, transparency, and trust in all our actions. At Sanofi, we believe that trust is the cornerstone of our relationships with stakeholders, partners, and the communities we serve. Our updated Code of Conduct reflects our dedication to upholding the highest ethical standards and fostering a culture of accountability and respect. 🔍 What's New? - Enhanced guidelines to ensure compliance with the latest regulations. - Clearer policies to support ethical decision-making. - Strengthened measures to protect patient safety and data privacy. We invite all our stakeholders to read and embrace this new edition. Together, we can continue to build a future where trust and excellence go hand in hand. Let's continue to make a difference, one ethical decision at a time. Thank you for your ongoing support and partnership! #Sanofi #Vaccines #Ethics #Compliance #Trust #Integrity

Sanofi, led by Paul Hudson CEO, continues to strengthen its presence in Latin America (LATAM) through a strategy focused on innovation, industrial expansion, and the adoption of advanced technologies. In LATAM, Sanofi operates key industrial sites, such as its facility in the State of Mexico, México, which produces essential medicines for the region and underscores the company's ongoing investment in local infrastructure. Sanofi has reinforced its position in LATAM with a portfolio of flagship products, including Dupixent and Lantus, designed to address chronic inflammatory diseases and diabetes, respectively. In 2024, Dupixent’s global sales rose by 23.8%, and its growing presence in emerging markets like LATAM highlights Sanofi’s commitment to delivering innovative therapies. The company has also solidified its vaccine portfolio, achieving a remarkable 25.5% increase in global vaccine sales. This growth was supported by enhanced production capacity for Beyfortus and reflects Sanofi's dedication to ensuring access to critical vaccines, including flu and pediatric immunizations, across LATAM. Sanofi is at the forefront of healthcare innovation, embracing artificial intelligence (AI) and digital health technologies to enhance patient care and streamline operations. The company has formed strategic partnerships with entities such as OpenAI and Formation Bio to develop predictive models for advancing research and personalizing treatments. In LATAM, these technologies are being leveraged to: 💉. Enhance Diagnostics: Using AI to identify patterns in prevalent chronic diseases like type 2 diabetes. 💉. Streamline Logistics: Employing big data analytics to forecast demand for medicines and vaccines across local markets. 💉. Empower Patients: Offering digital tools to help individuals better manage their treatments. Since becoming CEO, Paul has spearheaded a pipeline-focused transformation, prioritizing high-impact areas such as inflammatory diseases and cutting-edge vaccines. His leadership has also emphasized digitalization, aligning Sanofi’s global strategy with the unique needs of LATAM. Paul Hudson has reiterated the company’s commitment to emerging markets, stating: "Our ability to innovate and adopt cutting-edge technologies enables us to deliver next-generation treatments to patients worldwide, including those in Latin America." With global sales reaching €13,438 million in Q3 2024 (+15.7% at constant exchange rates) and a 67% increase in revenue from newly launched medicines, Sanofi anticipates continued growth in LATAM. The region remains a strategic priority, driven by the expansion of its product portfolio and sustained investments in infrastructure.

How can we build trust in #healthcare, together? 🤝 At Sanofi, trust is at the heart of everything we do — from our scientific research to our interactions patients, partners, and communities. Trust isn’t just a value we talk about; it’s a standard we work to uphold every day, guided by our Code of Conduct. As the world evolves, so does our Code. We’re updating and including essential areas like human rights, the responsible use of AI, and transparency on social media. Fostering a culture of accountability, openness, and continuous growth is essential to improve people's lives. 👀 Discover our Code of Conduct: http://spkl.io/6046fXtqn

How can we build trust in #healthcare, together? 🤝 At Sanofi, trust is at the heart of everything we do — from our scientific research to our interactions patients, partners, and communities. Trust isn’t just a value we talk about; it’s a standard we work to uphold every day, guided by our Code of Conduct. As the world evolves, so does our Code. We’re updating and including essential areas like human rights, the responsible use of AI, and transparency on social media. Fostering a culture of accountability, openness, and continuous growth is essential to improve people's lives. 👀 Discover our Code of Conduct: http://spkl.io/6046fXtqn #SerSanofi #SanofiStories

Attending the National Pharmaceutical Conference was amazing, yet again! The quality of the sessions was outstanding, but just as rewarding was the chance to reconnect with old friends and colleagues, sharing stories and ideas that remind us of the strength in our network. Between the expert panels and the informal moments in between, the conference highlighted the impact of collaboration and shared knowledge. Excited to carry these new insights forward and see where these renewed connections will lead! Here are my 3 key takeaways from the sessions: 1. AI & The Future of Human Health: A key takeaway on AI in healthcare is that its success depends on data quality—the old adage “Garbage In, Garbage Out” rings true. AI raises critical legal and ethical issues around inventorship, privacy (especially with cross-border data storage), and confidentiality, all of which demand strong safeguards. Balancing AI’s potential with these responsibilities is essential for ethical progress in healthcare. 2. Stand out: Standing out is more than just being seen; it’s about creating a meaningful impact that resonates with your audience. 3. Patient or profit centric? A controversial question we must consider is whether we are genuinely patient-centric or merely projecting a patient-centered image. This issue requires a deep, thoughtful look at how we define and measure success internally and where patient needs truly fit within our goals. Are we authentically putting patients first, or is it just a façade? #PharmaConference #IndustryInsights #HealthcareInnovation #ProfessionalNetworking #Nationalpharmaceuticalconference

🚀 New episode alert! 🎙️ In Episode 2, I dive into how AI is transforming clinical trials—tackling high costs, long timelines, and improving patient matching and adaptive designs. Let’s explore the tech + regulations shaping the future of drug development! 🎧 Listen: https://lnkd.in/edfresGU #AIInHealthcare #ClinicalTrials #HealthTech

Final Insights: Shaping the Future with Dario Health & Sanofi As our series on the transformative collaboration between Dario Health and Sanofi draws to a close, we reflect on the profound implications of aligning incentives in healthcare. This partnership has not just innovated the present—it's charting the course for the future. From pioneering GLP-1 therapies to leveraging cutting-edge digital platforms, Dario Health and Sanofi have demonstrated what's possible when two leaders unite with a shared vision. They've created a model that others in healthcare will follow, one where patient outcomes drive innovation and growth. What does this mean for healthcare? It's a shift towards a more empathetic, responsive, and efficient system, where every advancement brings us closer to the goal of accessible, personalized care. Thank you for joining us on this journey. Stay tuned for our next series, where we'll dive into the world of AI and ethics—a new frontier in healthcare innovation. 🔗 Revisit the partnership that's redefining healthcare: Final Article Link: https://lnkd.in/gVu2ArB2 #HealthcareFuture #PatientDrivenInnovation #Sanofi #DarioHealth #HealthcareSeries #TechInHealthcare Robert Horne, Forest Hill Labs: A Health Market Intelligence, Policy, and Thought Leadership Consultancy The Alliance for Artificial Intelligence in Healthcare (AAIH)

Authenticx partners with pharma manufacturers and life science enterprise to harness the ✨ power of conversations✨ to support patient access, brand insights, vendor management, and risk mitigation. Our technology leverages AI capabilities to aggregate and report on prevalent topics and trends. ➕ bonus: this conversation data likely already exists inside your organizations See how we work with Life Sciences to aggregate topics and trends by download our product guide ➡️ https://hubs.li/Q02GZxgM0

Ernest Hemingway famously said that people at first go bankrupt slowly, then all at once. When my father died during the dark days of the pandemic, it was his heart that failed at first slowly and then all at once. Or at least it seemed so to our distraught family. It turns out that my dad's heart condition has been recently identified as one of those common ailments that can be effectively fought using varied data sources from #wereables and #implantables. Such data must be collected, cleaned and annotated appropriately -that is another major challenge for public and private medical institutions and #digitalhealth companies- in order to be effectively leveraged. #AI and #bigdata are already playing a fundamental role in our health systems, and the sky is the only limit..well, almost the only one, as compliance with the ever enlarging body of digital legislation in the #EU and elsewhere is also paramount. We are truly excited to sponsor this event. #aiact #gdpr

𝗕𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗮𝗳𝗲𝘁𝘆 𝗶𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 ⚖️ In healthcare, the challenge of advancing AI while ensuring patient safety requires a fine balance. As one of the most 𝗵𝗲𝗮𝘃𝗶𝗹𝘆 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗲𝗱 𝘀𝗲𝗰𝘁𝗼𝗿𝘀, healthcare is now facing transformative 𝘀𝗵𝗶𝗳𝘁𝘀 𝗶𝗻 𝗔𝗜 oversight. ✔ 𝗧𝗵𝗲 𝗘𝗨 leads with a precautionary and prescriptive approach, implementing the 𝗽𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗔𝗜 𝗔𝗰𝘁—focusing on comprehensive risk assessment and strict compliance. This legislation is set to shape global regulatory trends. ✔ 𝗧𝗵𝗲 𝗨𝗞, meanwhile, is charting its course with an emphasis on flexibility and fostering innovation, 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗮 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 that can adapt to rapid technological changes. ✔ 𝗜𝗻 𝘁𝗵𝗲 𝗨𝗦, regulatory efforts are guided by foundational principles, with an evolving 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 designed to accommodate 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗔𝗜 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 in clinical settings. To thrive in this environment, organizations must stay ahead of these regulatory developments. Recent article by Sara Jaworska (Juszczyk), Quality and Regulatory Affairs Manager, offers a strategic overview of global efforts to 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗲 𝗔𝗜 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲. 👉 Explore the full analysis here: https://lnkd.in/e3kUeqnj #DataArtHealthcare #AI #Healthcare #Regulations